EGFR and neoplasm: Expression of CD73, CD39, HLA-E and NKp46 were mapped in tumor tissue from diagnosis, after progression on early-generation EGFR-TKIs and after progression on osimertinib given as next-line EGFR-therapy.<h4>Results</h4>Samples from 51 patients were evaluable.